Oslo Cancer Cluster Innovation Park

Oslo Cancer Cluster (OCC) is a Norwegian non-profit oncology cluster organisation founded in 2006 by Jonas Einarsson and Kaare Norum, designated in 2007 as Norway's only health-sector 'Norwegian Centre of Expertise' under a national scheme run jointly by Innovation Norway, the Research Council of Norway and state industrial-development agency SIVA. Its mission is to accelerate cancer diagnostics and treatment by connecting Oslo University Hospital/Radium Hospital, the Cancer Registry of Norway, universities, biotech startups and global pharmaceutical companies.

Its Innovation Park, opened in August 2015 at Montebello next to the Radium Hospital, cost roughly NOK 1 billion - about a quarter funded by SIVA and two-thirds by private investors - and today comprises 36,000 sqm housing the OCC Incubator, the Cancer Registry of Norway and hospital research institutes. Around 30 companies occupy 5,000 sqm of incubator space, with a further 12,000 sqm building due by late 2025 to host Thermo Fisher Scientific and a national cell-therapy centre. OCC now counts roughly 100 member organisations, including GSK, Novartis, Roche, AstraZeneca and Pfizer alongside Nordic biotechs. In December 2023, six member companies collectively secured NOK 92 million from the Research Council of Norway as part of a national NOK 494 million funding round; the cluster holds a Gold Label from the European Cluster Excellence Initiative, renewed in 2022 with a 94% score.

No independent, cluster-wide economic-impact study (aggregate jobs or total funding across all ~100 members) was found; the funding and membership figures available are per-programme snapshots rather than audited cumulative totals, and oncology drug development is inherently slow - OCC's own materials acknowledge that traditional trial methodologies are challenged by the small patient populations typical of precision cancer medicine.

Read the full analysis: https://oslocancercluster.no/